Atossa Genetics Inc. (NASDAQ:ATOS) Receives $36.33 Consensus Price Target from Analysts

Atossa Genetics Inc. (NASDAQ:ATOS) has been given a consensus recommendation of “Hold” by the five ratings firms that are presently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, two have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $36.3333.

Several research analysts recently weighed in on the stock. Ascendiant Capital Markets dropped their price objective on shares of Atossa Genetics from $120.00 to $24.00 and set a “buy” rating for the company in a research report on Friday, April 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Atossa Genetics in a research report on Monday, April 20th. Finally, HC Wainwright boosted their price objective on shares of Atossa Genetics to $25.00 and gave the stock a “buy” rating in a research report on Thursday, March 26th.

Atossa Genetics Price Performance

Shares of ATOS opened at $5.60 on Friday. The company has a market capitalization of $48.22 million, a P/E ratio of -1.56 and a beta of 1.25. Atossa Genetics has a one year low of $3.76 and a one year high of $19.35. The business’s 50 day simple moving average is $5.18 and its 200-day simple moving average is $8.28.

Atossa Genetics (NASDAQ:ATOS) last announced its earnings results on Friday, May 8th. The company reported ($1.11) EPS for the quarter, missing the consensus estimate of ($0.99) by ($0.12). On average, sell-side analysts anticipate that Atossa Genetics will post -4.58 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Hudson Bay Capital Management LP acquired a new position in Atossa Genetics during the 2nd quarter valued at about $26,000. Gallagher Capital Advisors LLC bought a new position in shares of Atossa Genetics in the 3rd quarter valued at about $27,000. JPMorgan Chase & Co. boosted its stake in shares of Atossa Genetics by 1,294.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 38,215 shares of the company’s stock valued at $33,000 after purchasing an additional 35,474 shares during the last quarter. &PARTNERS bought a new position in shares of Atossa Genetics in the 4th quarter valued at about $25,000. Finally, Bank of America Corp DE boosted its stake in shares of Atossa Genetics by 55.7% in the 2nd quarter. Bank of America Corp DE now owns 99,601 shares of the company’s stock valued at $83,000 after purchasing an additional 35,629 shares during the last quarter. Institutional investors own 12.74% of the company’s stock.

About Atossa Genetics

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.